Method using abnormally-activated-cell detection to test for malignant tumors and abnormally-activated-cell apheresis-therapy apparatus

A technology for activating cells and malignant tumors, which is used in the field of removing abnormal activated cells and returning blood circulation to the treatment device, which can solve the problems of increased indirect bilirubin concentration and the like

Active Publication Date: 2016-06-15
UNIV OKAYAMA
View PDF10 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Water-insoluble indirect bilirubin formed from heme in the body is usually converted into water-soluble direct (conjugated) bilirubin in the liver and excreted through the kidneys, but it i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method using abnormally-activated-cell detection to test for malignant tumors and abnormally-activated-cell apheresis-therapy apparatus
  • Method using abnormally-activated-cell detection to test for malignant tumors and abnormally-activated-cell apheresis-therapy apparatus
  • Method using abnormally-activated-cell detection to test for malignant tumors and abnormally-activated-cell apheresis-therapy apparatus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0124] (Example 1) Blood circulation reinfusion treatment device for removing abnormally activated cells

[0125] like Figure 5 As shown, the blood circulation reinfusion treatment device for removing abnormal activated cells is composed of the following: a blood collection pipeline 10 with a puncture needle (not shown) for blood collection at one end; blood samples supplied from the blood collection pipeline 10 A centrifugal separator 20 for separating white blood cells; a cell sorter 30 for removing abnormally activated cells such as leukemia cells from the white blood cells separated by the centrifugal separator 20; The normal white blood cell part of the activated cell is irradiated with light of a predetermined wavelength by the light irradiator 40; the blood is reinfused into the blood circulation composed of plasma components other than the white blood cell part separated by the centrifugal separator 20, red blood cell part and platelet part, etc. Blood circulation re...

reference example 1

[0139] (Reference Example 1) Confirmation of accumulation of PpIX using strained cells

[0140] In this reference example, the accumulation of intracellular PpIX after adding 1 mM 5-ALA to the culture solution of TLOm1 (ATLL leukemia cell line) was confirmed over time. It was confirmed that, as a result, after 5-ALA was added, PpIX was still sufficiently present in the cells after 48 hours ( figure 1 ). Moreover, CD3 / CD28 immune beads (CD3 / CD28, immuno-bead, Dynabeads) for peripheral blood mononuclear cells (PBMC) of healthy normal people (R) humanT-cellactivatorCD3 / CD28 (Invitrogen)) stimulated cells, and activated peripheral blood mononuclear cells (PBMC), TLOm1 and ED-40515 (ATLL leukemia cell line), administered 1mM 5- The accumulation of PpIX in cells at 48 hours after ALA was analyzed. As a result, specific accumulation of PpIX in activated T cells and tumor cells was confirmed ( figure 2 , image 3 ).

Embodiment 2

[0141] (Example 2) Confirmation of flow cytometry patterns of monocytes

[0142] In this example, the confirmation of the flow cytometry pattern was performed on the peripheral blood mononuclear cells (PBMC) isolated from the peripheral blood of healthy normal people, HTLV-I carriers or ATLL patients. 1 mM 5-ALA was added to the culture medium containing each peripheral blood mononuclear cell (PBMC) and cultured for 48 hours. For these cells, the accumulation of PpIX and the expression of TSLCI were confirmed, and the cell distribution pattern was analyzed by flow cytometry. analysis. As a result, for (1) healthy normal people, (2) low-risk HTLV-I carriers, (3) medium-risk HTLV-I carriers, (4) high-risk HTLV-I carriers, ( 5) Peripheral blood mononuclear cells (PBMC) from patients with smoldering ATLL, (6) patients with chronic ATLL and (7) patients with acute ATLL confirmed their unique cell distribution patterns ( Figure 4 ). Although the lifetime risk of ATLL for HTLV-I ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Wavelengthaaaaaaaaaa
Login to view more

Abstract

This invention provides an abnormally-activated-cell apheresis-therapy apparatus for inhibiting the onset of or treating leukemia by removing abnormally activated cells, specifically abnormally activated leukocytes or leukemia progenitor cells, from blood. Said abnormally-activated-cell apheresis-therapy apparatus, which is an abnormally-activated-leukocyte apheresis-therapy apparatus that removes abnormally activated cells such as leukemia cells from blood, said cells having been made identifiable via high-concentration accumulation of protoporphyrin IX, is provided with the following: a blood-collection line, one end of which is provided with a needle for blood collection; a centrifugal separator that separates out a leukocyte fraction from blood sent down the blood-collection line; a cell sorter that removes abnormally activated cells from the separated-out leukocyte fraction; a light-exposure device that exposes the normal leukocyte fraction resulting from the removal of the aforementioned abnormally activated cells to light of a prescribed wavelength; and a return line that returns, to the patient, the normal leukocyte fraction and a return fluid comprising the blood components other than the leukocyte fraction.

Description

technical field [0001] The invention relates to a method for checking malignant tumors based on detection of abnormal activated cells and a blood circulation reinfusion treatment device for removing abnormal activated cells. In more detail, it relates to a treatment device for removing abnormally activated cells and returning blood to blood circulation for inhibiting or treating the onset of leukemia by removing abnormally activated cells. [0002] This application claims the priority of Japanese application No. 2013-130758, which is incorporated herein by reference. Background technique [0003] Recently, in Japan, the incidence of leukemia tends to increase year by year. The number of deaths due to leukemia was about 11,156 in 2008, which is 8.8 per 100,000 population (10.5 for men and 7.1 for women). [0004] In particular, adult T-cell leukemia / lymphoma (adult T-cellleukemia / lymphoma: ATLL) is known as refractory leukemia / lymphoma. Among the carriers of the human T-ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/49A61M1/02A61M1/36G01N33/574
CPCA61M1/3496A61M1/3681A61M1/3693A61M1/3696A61M2202/0439
Inventor 冈刚史藤田洋史吉野正
Owner UNIV OKAYAMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap